Spectrum Pharmaceuticals

.

FDA OK’s Spectrum Cancer Drug for Wider Use

Spectrum Pharmaceuticals

An Irvine drug maker, Spectrum Pharmaceuticals Inc., has said that it got regulatory approval for an expanded use of a cancer drug.

Spectrum said that the FDA approved Zevalin as an early treatment for a blood cancer, in patients with non-Hodgkin's lymphoma. The drug was used previously on patients whose tumors did not respond to other treatments.

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics

Spectrum Pharmaceuticals inks 50:50 JV pact with Cell Therapeutics Spectrum Pharmaceuticals and Cell Therapeutics have entered into an agreement to form a 50:50 owned joint venture, RIT Oncology, to commercialize and develop Zevalin in the United States.

Latest News

Though Wages in Japan Increase But It’s not Enough to Beat Inflation
Jack Ma Prepares for Second Alibaba IPO
RBA Feels Currency Overrated: Keeps Record Low Benchmark Rate
U.S. Business Lobby Express Concerns Saying Antitrust Probes in China Unfair
First dengue fever outbreak in 70 years in Japan
Rise in skin cancer due to cheap holidays
Cardio and wine is a great combination
Surrogacy is a form of exploitation: Ekman
Cuba Trims Down on Amount of Goods Which can be Carried by Travellers
Barclays Will Sell Its Spanish Businesses To CaixaBank In a Deal of 800 Million
Withdrawal in China’s Purchasing Managers' Index Amplifies Calls for Policy Easi
The Ukraine Mayhem Leads Euro to a Fresh One Year Low
Syndicate content